Project Grant R41AI197642
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $296K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Stony Brook, NY 11790, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $800,557 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the pathogen Staphylococcus aureus manipulates inflammasome activities critical to host defense. The funded research identifies mechanisms by which diverse S. aureus strains, including toxigenic and non-toxigenic variants, activate inflammasome regulatory proteins in immune cells....
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $599,327 to Microbiotix, Inc. on September 22, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel benzyl-piperidine antifungal agents targeting intractable mucormycosis infections caused by drug-resistant Mucorales fungi. The project focuses on chemical optimization of a benzyl-piperidine series to improve drug-like properties and...
- The National Heart, Lung, and Blood Institute awarded Cmtx Biotech Inc. $367,988 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a lung-specific, sulfonium lipid nanoparticle formulation of Incyclinide (CMT-3/SLNP) for treating acute respiratory distress syndrome in sepsis patients. This Phase I Small Business Technology Transfer project will evaluate the formulation and delivery of CMT-3/SLNP, a chemically modified, non-antibiotic tetracycline...
- The National Institute of Allergy and Infectious Diseases awarded $320,863 to Celdara Medical, LLC on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop CM-HZ01, a high-avidity interleukin-2 super agonist for treatment of osteomyelitis. Celdara will streamline production of CM-HZ01, demonstrate its ability to expand cytotoxic CD8 and natural killer cells under bacterial challenge, and evaluate the agent in a rodent osteomyelitis model while...
- The National Institute of Allergy and Infectious Diseases awarded Iaso Therapeutics Inc. $599,998 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a multi-antigen Staphylococcus aureus vaccine using a proprietary mutant bacteriophage platform. Iaso will conduct two research aims over the period of performance through June 30, 2028. In Aim 1, the company will evaluate the protective efficacy of an MQB-PNAG26 conjugate vaccine in a S. aureus...
- The National Institute of Allergy and Infectious Diseases awarded New York University $218,728 on December 22, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the role of skin pathobionts in cutaneous T cell lymphoma. The research investigates whether Staphylococcus aureus colonization contributes to cutaneous T cell lymphoma (CTCL) progression. The study addresses three primary questions: whether S. aureus is enriched in CTCL patient skin microbiomes...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $233,250 for Project Grant R21AI201981 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into cethromycin-based treatment regimens for Mycobacterium avium disease. The study will evaluate whether cethromycin, a next-generation macrolide (ketolide), offers superior efficacy over current standard-of-care multidrug therapies. M. avium is...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $3,064,333 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how the host immune response influences methicillin-resistant Staphylococcus aureus susceptibility to antibiotics in skin and soft tissue infections. The research comprises three specific aims. Aim 1 examines how neutrophils enriched during the...
- Federal Project Grant Award Summary Award Details: Abvacc, Inc. received a $638,953 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award was issued on August 22, 2025, with a completion date of July 31, 2030, and performance will be conducted in Rockville, Maryland. Products and Services: The grant funds development of an immunotherapeutic antibody cocktail for treating...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Stony Brook University a $3.13 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 23, 2025, with completion targeted for June 30, 2029. The grant funds research to develop new therapeutic strategies targeting STS-1 and STS-2 phosphatases as a means to enhance antimicrobial immune responses. The project deliverables include the identification...